Comments to CMS on the International Pricing Index Model for Medicare Part B Drugs Recommending Consideration of the Impact of Policy Changes on Employer Plans

The National Business Group on Health submitted comments to the CMS Administrator’s advanced notice of proposed rulemaking on the International Pricing Index for Part B Drugs recommending that any changes to the Medicare policies don’t shift costs to employer plans and that changes to “buy and bill” practices do not accelerate market consolidation and vertical integration of oncology and rheumatology practices.